Benjamin Daquioag.
Phone number 713-526-9821 ext217

BI1220.48

A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment

Copyright © 2017. Cure C Consortium